Emmaus Medical recently received FDA (The U.S. Food and Drug Administration) approval for sickle cell disease therapy Endari (L-gluitamine), ending two decades of drought for treatment of the disease and giving an alternative to the only other drug on the market, hydroxyurea.
Recently, Terry Yuan, the founder and CEO of Ddu, revealed that Ddu (www.drugdu.com) has raised 10 million yuan in Series Pre-A round of financing, which will be used to improve the service and build a strong team. Ddu is a global leading pharmaceuticals and medical devices online B2B platform.
With the improvement of living standards and the enhancement of health consciousness, people’s investment in healthcare has been increased. In recent years, the scale of China's rehabilitation consumables market has been increased year by year.
Both the Shanghai CMEF 2017 and Sao Paulo Hospitalar 2017 came to an end recently. As a global leading pharmaceutical and medical device B2B online platform, Ddu attended the two fairs, showcasing products of high priority users.
In which industry is the next unicorn company most likely to be born into? With the arrival of an aging society, medical trade is regarded as the industry with the most potential to produce a unicorn company.
Aspen Pharmacare is under investigation by the European Commission over its pricing practices for five cancer medicines.
Drugdu Technology Co., Ltd., a developer of the leading global pharmaceutical and medical device B2B platform Drugdu.com (Ddu), today announced that it will attend Hospitalar 2017 from May 16 to 19 in Sao Paulo, Brazil. Drugdu.com will showcase products of premium members and deliver innovative solutions, which are attractive not only for its users, but for the whole healthcare industry.
GlaxoSmithKline and Innoviva have unveiled data from a second ground-breaking Salford Lung Study (SLS) showing that Relvar Ellipta significantly improved asthma control versus patients’ standard therapy.
WHO is improving transparency and accountability with the launch of a redesigned Programme Budget Web Portal that makes budget and spending information easier to access, use and understand.
Patients with a rare form of leukaemia look set to win routine access to a novel treatment option on the NHS in England and Wales after Amgen’s Blincyto was backed by cost watchdog NICE
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.